Table 2.
Ki-67 as a predictor of clinically significant outcomes
| Outcome: Biochemical recurrence | |||
|---|---|---|---|
| HR | 95 % CI | p-value | |
| Univariate model | |||
| Ki-67*,& | 1.29 | 0.97-1.73 | 0.019 |
| Multivariate model | |||
| Ki-67*& | 1.46 | 1.10-1.94 | 0.009 |
| PSA (μg/L) | 1.02 | 1.01-1.03 | <0.001 |
| Gleason Score& | 1.09 | 0.94-1.26 | 0.25 |
| pT3N + M+ | 1.47 | 1.17-1.84 | <0.001 |
| Age (years) | 0.96 | 0.93-0.99 | 0.02 |
| Outcome: Death from prostate cancer | |||
| HR | 95 % CI | p-value | |
| Univariate model | |||
| Ki-67& | 1.19 | 1.01-1.41 | 0.040 |
| Multivariate model | |||
| Ki-67& | 1.26 | 1.06-150 | 0.010 |
| PSA (μg/L) | 1.01 | 0.98-1.04 | 0.577 |
| Gleason Score& | 1.30 | 0.79-2.14 | 0.293 |
| pT3N + M+ | 3.49 | 1.19-10.23 | 0.022 |
| Age (years) | 0.97 | 0.86-1.08 | 0.554 |
Ki-67*: The square root of Ki-67; PSA: Prostate-specific antigen; HR: Hazard ratio; CI: Confidence interval
&Ki-67 was assessed as a continuous variable. Gleason score was dichotomized to <7 vs ≥ 7